Development of a Risk Predictive Model for Evaluating Immune Infiltration Status in Invasive Thyroid Carcinoma

Figure 7

Mutation analysis and drug sensitivity analysis. (a) The drugs with IC50 < 1 for all tumor samples in TCGA cohort; (b) heatmap shows the differences on IC50 value (evaluation for drug sensitivity) for immune-activated and immunosuppressive patients; (c) risk score significantly differed between immune-activated and immunosuppressive patients; (d) tumor mutation burden shows no differences between immune-activated and immunosuppressive patients; (e) statistical result of somatic mutation for all tumor samples in TCGA cohort; (f) waterfall plot shows the top 20 mutation genes; (g) correlation analysis between tumor-infiltrating immune cells evaluated by CIBERSORTx and genes in model.

(a)

(b)

(c)

(d)

(e)

(f)

(g)